The end of the heparin pump?: Low molecular weight heparin has many advantages over unfractionated heparin

BMJ

Volumn 317, Issue 7172, 1998, Pages 1540-1542

  Grubb, Neil R ^a   Bloomfield, Peter ^a   Ludlam, Christopher A ^a  

^a ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN;

COST BENEFIT ANALYSIS; DRUG COST; DRUG EFFICACY; EDITORIAL; HUMAN; INFUSION PUMP; PRIORITY JOURNAL; THROMBOSIS PREVENTION; UNSTABLE ANGINA PECTORIS; VEIN THROMBOSIS;

ANGINA, UNSTABLE; HEPARIN; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; INFUSION PUMPS; THROMBOEMBOLISM;

EID: 0032488326     PISSN: 09598138     EISSN: 14685833     Source Type: Journal    
DOI: 10.1136/bmj.317.7172.1540     Document Type: Editorial

References (13)

1. Antman EM and the TIMI 9B Investigators. Hirudin in acute myocardial infarction. Thrombolysis and thrombin inhibition in myocardial infarction (TIMI) 9B trial. Circulation 1996; 94: 911–921.
2. Barritt DW, Jordan SC. Anticoagulant drugs in the treatment of pulmonary embolism: A controlled trial. Lancet 1960; 1: 1309.
3. Oler A, Whooley MA, Oler J, Grady D. Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina. JAMA 1996; 276: 811–815.
4. Klein W, Buchwald A, Hillis WS, Monrad S, Sanz G, Turpie AGG, et al. Fragmin in unstable angina pectoris or in non-Q-wave acute myocardial infarction (the FRIC study). Am J Cardiol 1997; 80: 30E–34E.
5. Cohen M, Demers C, Gurfinkel E, Turpie AGG, Fromell GJ, Goodman S, et al. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. N Engl J Med 1997; 337: 447–452.
6. Hull RD, Raskob GE, Pineo GF, Green D, Trowbridge AA, Elliott CG, et al. Subcutaneous low-molecular weight heparin versus subcutaneous unfractionated heparin in the treatment of deep venous thrombosis. N Engl J Med 1992; 326: 975–982.
7. Lensing AWA, Prins MH, Davidson BL, Hirsh J. Treatment of deep venous thrombosis with low molecular weight heparins: A meta-analysis. Arch Int Med 1995; 155: 601–607.
8. Levine M, Gent M, Hirsh J, Leclerc J, Anderson D, Weitz J, et al. A comparison of low molecular weight heparin administered primarily at home with unfractionated heparin administered in hospital for proximal deep venous thrombosis. N Engl J Med 1996; 334: 677–681.
9. Koopman MMW, Prandoni P, Piovella F, Ockelford PA, Brandjes DPM, van der Meer J, et al. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low molecular weight heparin administered at home. N Engl J Med 1996; 334: 682–687.
10. Simonneau G, Sors H, Charbonnier B, Page Y, Laaban JP, Azarian R, et al. A comparison of low molecular weight heparin with unfractionatedheparin for acute pulmonary embolism. The THESEE Study Group. Tinzaparine ou Heparine Standard: Evaluations dans l'Embolie Pulmonaire. N Engl J Med 1997; 337: 663–669.
11. Palmer AJ, Koppenhagen K, Kirchhof B, Weber U, Bergemann R. Efficacy and safety of low molecular weight heparin, unfractionated heparin, and warfarin for thromboembolism prophylaxis in orthopaedic surgery: A meta-analysis of randomised clinical trials. Haemostasis 1997; 27: 75–84.
12. Geerts WH, Jay RM, Code KI, Chen E, Szalai JP, Saibil EA, et al. A comparison of low dose heparin with low molecular weight heparin as prophylaxis against venous thromboembolism after major trauma. N Engl J Med 1996; 335: 701–707.
13. Fox KAA, Bosanquet N. Assessing the UK cost implications of the use of low molecular weight heparin in unstable coronary artery disease. Br J Cardiol 1998; 5: 92–105.